Print page content Print
Increase text size Decrease text size
Text Size

CYTOPOINT® works fast and lasts

CYTOPOINT provides relief of allergic itch within 24 hours that lasts for 4 to 8 weeks1,2

A single injection of CYTOPOINT was shown to significantly decrease IL-31-induced pruritus in dogs within one day of injection and for 28 days2

Pruritis reduction graph

*Least squares mean (±SE).

Day -7 means are arithmetic mean values.

Statistically significant (P<0.0001) compared to placebo.

In the pivotal efficacy study, the majority of atopic dogs achieved treatment success with a single injection1

Relief success graph
VAS score graph

*Repeat administration every 4 to 8 weeks as needed in individual patients.1

Successful canine pruritus relief was defined as a reduction in pruritus score of ≥20 mm on the visual analog scale (VAS). VAS is an owner-assessed scale that measures itch along a continuum from normal dog (no itch) to extremely severe itch, using numbers from 0 to 100. VAS scoring instruments were given to owners, accompanied by explanations of how to record itch based on the behavior of the dog. Owners recorded itch on Days 1, 2, 3, 7 and every 7 days thereafter.1

Statistically significant compared to placebo (P≤0.05).

§Day 0 means are arithmetic mean values.

Achieve treatment success with CYTOPOINT

Subsequent injections of CYTOPOINT were shown to help dogs who did not achieve treatment success with their first injection3

In a 2019 study, additional CYTOPOINT injections worked for dogs with atopic dermatitis who needed more time to achieve lasting relief3

1st injection

First injection success aligns with pivotal study data

2nd injection

Even more dogs achieve itch relief after the second injection

3rd injection

Nearly all dogs in the study experience relief after the third injection

CYTOPOINT was proven to work fast and last in dogs with allergic dermatitis4

achieved with a single injection of CYTOPOINT4*

  • 82% of dogs with allergic dermatitis of undetermined cause were treatment successes
  • Dogs with food allergies and atopic dermatitis were also treatment successes with CYTOPOINT

*The ~9 out of 10 treatment success rate reflects that 116 out of 132 dogs with any type of allergic dermatitis were treatment successes (87.8%). 45 dogs with allergic dermatitis of undetermined cause are included in that group. 37 of the 45 achieved treatment success, resulting in an 82% success rate.

  • 93% of large/giant dogs (48.7 lb) were treatment successes

CYTOPOINT offered lasting relief for dogs big and small4

Indications: CYTOPOINT has been shown to be effective for the treatment of dogs against allergic dermatitis and atopic dermatitis.

References: 1. Data on file, Study Report No. C863R-US-12-018, 2014, Zoetis Inc. 2. Data on file, Study Report No. C166R-US-17-180, 2018, Zoetis Inc. 3. Data on file, Outcomes Research Study No. 17SP4DER-01-01, 2019, Zoetis Inc. 4. Souza CP, Rosychuk RAW, Contreras ET, et al. A retrospective analysis of the use of lokivetmab in the management of allergic pruritus in a referral population of 135 dogs in the western USA. Vet Dermatol. 2018;29(6):489-e164. doi:10.1111/vde.12682.

This site is intended for U.S. Animal Healthcare Professionals. The animal health information contained herein is provided for educational purposes only and is not intended to replace discussions with an animal healthcare professional. All decisions regarding the care of a veterinary patient must be made with an animal healthcare professional, considering the unique characteristics of the patient.

The product information provided in this site is intended only for residents of the United States. The products discussed herein may not have marketing authorization or may have different product labeling in different countries. 

All trademarks are the property of Zoetis Services LLC or a related company or a licensor unless otherwise noted.
© 2020 Zoetis Services LLC. All rights reserved. CYT-00444

CONTACT US

1-888-963-8471

We are Mon–Fri, 8:30am–8:00pm ET

This site is intended for U.S. Animal Healthcare Professionals. The product information provided in this site is intended only for residents of the United States. The products discussed herein may not have marketing authorization or may have different product labeling in different countries. The animal health information contained herein is provided for educational purposes only and is not intended to replace discussions with an animal healthcare professional. All decisions regarding the care of a veterinary patient must be made with an animal healthcare professional, considering the unique characteristics of the patient.

All trademarks are the property of Zoetis Services LLC or a related company or a licensor unless otherwise noted. ©2020 Zoetis Services LLC. All rights reserved.